Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates

Gene Therapy

Volumn 8, Issue 20, 2001, Pages 1580-1586

  Roberts, M L ^a   Athanasopoulos, T ^a   Pohlschmidt, M ^a   Duisit, G ^b   Cosset, F L ^c   Dickson, G ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

Adenovirus; Hybrid vector; MDX; Muscle; Retrovirus

Indexed keywords

APHIDICOLIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DIFFERENTIATION; DNA TEMPLATE; MITOSIS; MOUSE; MUSCLE CELL; MUSCLE DEVELOPMENT; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; VIRUS HYBRID; VIRUS INFECTION;

3T3 CELLS; ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; APHIDICOLIN; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; MICROSCOPY, FLUORESCENCE; MUSCLE FIBERS; MUSCULAR DYSTROPHY, DUCHENNE; RETROVIRIDAE;

EID: 0035157991     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301555     Document Type: Article

References (38)

1. Duchenne muscular dystrophy - Meryon's disease
2. Expression of a recombinant dystrophin in mdx mice using adenovirus vector
3. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer
4. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
5. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles
6. Adenoviral vectors for gene transfer of full-length human dystrophin cDNAs
7. Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency
8. Adenovirus as an expression vector in muscle cells in vivo
9. Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle
10. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs
11. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene
12. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo
13. Developments in gene therapy for muscular dystrophy
14. Human serum lyses RNA tumor viruses
15. Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the beta-galactosidase gene in the non-infarcted area, but not the myocardial infracted area
16. Genetic modification of the hematolymphoid compartment for therapeutic purposes
17. Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I
18. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
19. Transplantation of retroviral producer cells for in vivo gene transfer into mouse skeletal muscle
20. Genetic correction of dystrophin deficiency and skeletal muscle remodelling in adult mdx mouse via transplantation of retroviral producer cells
21. Adeno-retroviral chimeric viruses as in vivo transducing agents
22. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
23. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector
24. Construction of new retroviral producer cells from adenoviral and retroviral vectors
25. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors
26. Chimeric viral vectors - The best of both worlds?
27. Production of defective virus by terminally differentiated myotubes infected with rous sarcoma virus
28. Methods for construction of adenovirus vectors
29. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
30. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle
31. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants
32. Packaging cell line characteristics and optimizing retroviral vector titer: The National Gene Vector Laboratory Experience
33. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium
34. Improved methods of retroviral vector transduction and production for gene therapy
35. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line
36. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA
37. Gene therapy vectors based on adeno-associated virus: Characteristics and applications to acquired and inherited diseases
38. Technology evaluation: AAV factor IX gene therapy, Avigen Inc